Prothena (PRTA) Set to Announce Earnings on Tuesday

Prothena (NASDAQ:PRTA) is scheduled to post its quarterly earnings results after the market closes on Tuesday, November 12th. Analysts expect Prothena to post earnings of ($1.18) per share for the quarter.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.01) by $2.23. The firm had revenue of $132.01 million during the quarter, compared to analysts’ expectations of $10.73 million. Prothena had a negative net margin of 23.44% and a negative return on equity of 9.00%. The firm’s quarterly revenue was up 3184.7% on a year-over-year basis. During the same quarter last year, the company posted ($1.03) EPS. On average, analysts expect Prothena to post $-2 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Prothena Stock Up 1.2 %

Shares of NASDAQ PRTA opened at $17.70 on Monday. Prothena has a 52-week low of $15.30 and a 52-week high of $41.54. The business’s 50 day moving average is $18.65 and its two-hundred day moving average is $20.48. The firm has a market cap of $951.91 million, a price-to-earnings ratio of -17.70 and a beta of 0.16.

Analyst Ratings Changes

Several equities analysts recently issued reports on PRTA shares. Cantor Fitzgerald restated an “overweight” rating on shares of Prothena in a report on Monday, September 30th. Royal Bank of Canada lowered their price objective on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $84.00 target price on shares of Prothena in a research note on Tuesday, October 1st. StockNews.com raised shares of Prothena from a “sell” rating to a “hold” rating in a research report on Monday, August 12th. Finally, Oppenheimer cut their price objective on Prothena from $66.00 to $62.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 14th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Prothena has a consensus rating of “Moderate Buy” and a consensus price target of $61.86.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.